Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | |||||
---|---|---|---|---|---|---|---|---|
Past history of cancer | 70 | [41–98] | 82.5 | [70–94] | 50.0 | [23–76] | 91.7 | [82–100] |
BDG > 80 | 70 | [41–98] | 42.5 | [27–57] | 23.3 | [8–38] | 85.0 | [69–100] |
mHLA-DR < 5000 | 60 | [29–90] | 57.5 | [42–72] | 26.1 | [8–44] | 85.2 | [71–98] |
Total lymphocytes < 500 | 80 | [55–100] | 45 | [29–60] | 26.7 | [10–42] | 90.0 | [76–100] |
CD4+T cells < 200 | 80 | [55–100] | 60 | [44–75] | 33.3 | [14–52] | 92.3 | [82–100] |
Association of markers | ||||||||
mHLA-DR < 5000 and BDG > 80 | 40 | [9–70] | 80 | [67–92] | 33.3 | [6–60] | 84.2 | [72–95] |
Total lymphocytes < 500 and BDG > 80 | 70 | [41–98] | 62.5 | [47–77] | 31.8 | [12–51] | 89.3 | [77–100] |
CD4+T cells < 200/mm3 and BDG > 80 | 70 | [41–98] | 70 | [55–84] | 36.8 | [15–58] | 90.3 | [79–100] |
Past history of cancer and mHLA-DR < 5000 | 50 | [19–81] | 90 | [80–99] | 55.6 | [23–88] | 87.8 | [77–97] |